🔎 Trials Near Me

Hjem › Skizofreni › Illinois

Skizofreni kliniske forsøg i Illinois

26 studier for Skizofreni søger deltagere på steder i Illinois.

Byer i Illinois

Officiel studietekst (engelsk)

Cognitive Neurocomputational Task Reliability & Clinical Applications Consortium (CNTRACS): Study 1

  • The University of Chicago, Chicago
RekruttererFrivillige med god helbredstilstand velkomne
Alder 18 til 59 · Alle køn · Opdateret 2. okt. 2026 · NCT07853807

Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

  • Evanston Hospital, Evanston
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT07101094

A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia

  • Uptown Research Institute, Chicago
RekruttererFase 1
Alder 18 til 55 · Alle køn · Opdateret 28. sep. 2026 · NCT07615426

Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

  • Local Institution - 0067, Chicago
  • Pillar Clinical Research -Chicago, Chicago
RekruttererFase 3
Alder 18 til 65 · Alle køn · Opdateret 28. sep. 2026 · NCT07686263

Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

  • Baber Research Group, Naperville
RekruttererFase 3
Alder 5 til 17 · Alle køn · Opdateret 25. sep. 2026 · NCT06229210

NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

  • Neurocrine Clinical Site, Chicago
  • Neurocrine Clinical Site, Oak Brook
RekruttererFase 3
Alder 18 til 65 · Alle køn · Opdateret 25. sep. 2026 · NCT07114874

A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents

  • Local Institution - 0175, Chicago
  • EmVenio Research Center - Prime Healthcare, Chicago
RekruttererFase 3
Alder 5 til 17 · Alle køn · Opdateret 22. sep. 2026 · NCT07424404

A Study of Brenipatide in Adult Participants With Schizophrenia

  • Re:Cognition Health - Chicago, Chicago
RekruttererFase 2
Alder 18 til 55 · Alle køn · Opdateret 22. sep. 2026 · NCT07410507

52-week Open Label Safety-Tolerability Study

  • Pillar Clinical Research, Chicago
RekruttererFase 3
Alder 18 til 65 · Alle køn · Opdateret 9. sep. 2026 · NCT07369154

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

  • Local Institution - 0122, Chicago
  • EmVenio Research Center - Prime Healthcare, Chicago
RekruttererFase 3
Alder 13 til 17 · Alle køn · Opdateret 4. sep. 2026 · NCT07288567

A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT

  • Uptown Research Institute, Chicago
RekruttererFase 1
Alder 18 til 55 · Alle køn · Opdateret 2. sep. 2026 · NCT07061288

A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

  • Clinical Site, Chicago
RekruttererFase 2
Alder 18 til 65 · Alle køn · Opdateret 1. sep. 2026 · NCT07459647

Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

  • Local Institution - 0046, Crystal Lake
  • Amr Conventions Research - Illinois, Warrenville
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 19. aug. 2026 · NCT07379827

Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

  • Alkermes Investigator Site, Chicago
RekruttererFase 3
Alder 10 til 17 · Alle køn · Opdateret 14. aug. 2026 · NCT05303064

Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia

  • Uptown Research Institute LLC, Chicago
  • Pillar Clinical Research LLC, Chicago
RekruttererFase 2
Alder 18 til 65 · Alle køn · Opdateret 29. jul. 2026 · NCT07467993

Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia

  • Pillar Clinical Research, Chicago
RekruttererFase 3
Alder 18 til 65 · Alle køn · Opdateret 27. jul. 2026 · NCT07363577

Transition Care for FEP

  • University of Chicago Ingalls Memorial Hospital, Harvey
RekruttererObservationsstudie
Alder 18 til 40 · Alle køn · Opdateret 20. jul. 2026 · NCT07713849

A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia

  • Uptown Research Institute, Chicago
RekruttererFase 2
Alder 18 til 55 · Alle køn · Opdateret 23. jun. 2026 · NCT07191483

A Study to Evaluate the Effect of KarXT on Urological Safety

  • Uptown Research Institute, Chicago
  • Pillar Clinical Research -Chicago, Chicago
RekruttererFase 4
Alder 18 til 65 · Alle køn · Opdateret 3. jun. 2026 · NCT07221877

CLOZAPINE Response in Biotype-1

  • University of Chicago, Chicago
RekruttererFase 4
Alder 18 til 60 · Alle køn · Opdateret 11. maj 2026 · NCT04580134

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

  • University of Chicago Medical Center, Chicago
RekruttererObservationsstudie
Alder 18 til 40 · Alle køn · Opdateret 10. mar. 2026 · NCT06740383

NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

  • Neurocrine Clinical Site, Chicago
RekruttererFase 3
Alder 18 til 65 · Alle køn · Opdateret 6. mar. 2026 · NCT06963034

Randomized Withdrawal Study in Patients With Schizophrenia

  • Vanda Investigational Site, Chicago
RekruttererFase 3
Alder 18 til 65 · Alle køn · Opdateret 12. jan. 2026 · NCT06961968

Study of ALTO-101 in Patients With Schizophrenia

  • Site 5056, Chicago
RekruttererFase 2
Alder 21 til 55 · Alle køn · Opdateret 26. dec. 2025 · NCT06502964

Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

  • Reviva site, Chicago
RekruttererFase 3Frivillige med god helbredstilstand velkomne
Alder 18 til 65 · Alle køn · Opdateret 19. dec. 2024 · NCT05184335

Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.